In June 2020, the article 'Brain Penetrable Inhibitors of Ceramide Galactosyltransferase for the Treatment of Lysosomal Storage Disorders' ( describing the discovery of "Compound 19" as a selective brain-penetrant inhibitor of the ceramide galactosyltransferase UGT8 was published. This drug candidate shows excellent oral PK/PD in the brain model and is intended for use in substrate reduction therapy for rare lysosomal storage disorders (e.g. Metachromatic Leukodystrophy, MLD). "Compound 19" contains thieno[3,2-b]pyridine moiety in its backbone.

We have made a set of compounds, which contain such part – the perfect start for your research!